Gaia Cusumano

Dr. Gaia Cusumano

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
GCGaia Cusumano
Gaia Cusumano
Giancarlo Angeles FloresGiancarlo Angeles Flores
Giancarlo Angeles Flores
RVRoberto Venanzoni
Roberto Venanzoni
Paola AngeliniPaola Angelini
Paola Angelini
The human gut microbiota—an intricate and dynamic ecosystem—plays a pivotal role in metabolic regulation, immune modulation, and the maintenance of intestinal barrier integrity. Although antibiotic therapy is indispensable for managing bacterial infections, it profoundly disrupts gut microbial communities. Such dysbiosis is typified by diminished diversity and shifts in community structure, especially among beneficial bacterial genera (e.g., Bifidobacterium and Eubacterium), and fosters antibiotic-resistant strains and the horizontal transfer of resistance genes. These alterations compromise colonization resistance, increase intestinal permeability, and amplify susceptibility to opportunistic pathogens like Clostridioides difficile. Beyond gastrointestinal disorders, emerging evidence associates dysbiosis with systemic conditions, including chronic inflammation, metabolic syndrome, and neurodegenerative diseases, underscoring the relevance of the microbiota–gut–brain axis. The recovery of pre-existing gut communities post-antibiotic therapy is highly variable, influenced by drug spectrum, dosage, and treatment duration. Innovative interventions—such as fecal microbiota transplantation (FMT), probiotics, synbiotics, and precision microbiome therapeutics—have shown promise in counteracting dysbiosis and mitigating its adverse effects. These therapies align closely with antibiotic stewardship programs aimed at minimizing unnecessary antibiotic use to preserve microbial diversity and curtail the spread of multidrug-resistant organisms. This review emphasizes the pressing need for microbiota-centered strategies to optimize antibiotic administration, promote long-term health resilience, and alleviate the disease burden associated with antibiotic-induced dysbiosis.

23 December 2024 in Processes
Verified
Journal Article
Open access
PDF file
ECEleonora Calzoni
Eleonora Calzoni
ABAgnese Bertoldi
Agnese Bertoldi
GCGaia Cusumano
Gaia Cusumano
Sandra BurattaSandra Buratta
Sandra Buratta
Lorena UrbanelliLorena Urbanelli
Lorena Urbanelli
Carla EmilianiCarla Emiliani
Carla Emiliani
Plant-derived extracellular vesicles (PDEVs) are lipid bilayer nanoparticles, naturally produced by plant cells, with sizes ranging from 50 to 500 nm. Recent studies have highlighted their great potential in the biotechnological and medical fields, due to their natural origin, high biocompatibility and intrinsic therapeutic properties. PDEVs contain a complex biological cargo of proteins, lipids, nucleic acids and secondary metabolites, including antioxidants and anti-inflammatory molecules, making them ideal for biomedical applications such as drug delivery. These vesicles play a key role in intercellular communication and gene regulation, proving to be particularly promising in personalized medicine. Recent studies have highlighted their ability to improve drug stability and bioavailability, optimizing targeted release and minimizing side effects. Despite some challenges, such as compositional variability and the need for standardized protocols, PDEVs are at the gunsight of innovative research aimed at improving their loading capacity and therapeutic specificity. This review aims to provide a comprehensive overview of PDEVs, exploring their structure, isolation methods, functional characteristics, and applications, highlighting their advantages over synthetic nanoparticles and animal-derived extracellular vesicles, leading to an innovative and sustainable solution for the development of new therapeutic approaches.

6 July 2024 in Polysaccharides
Verified
Journal Article
Open access
PDF file
Giancarlo Angeles FloresGiancarlo Angeles Flores
Giancarlo Angeles Flores
GCGaia Cusumano
Gaia Cusumano
RVRoberto Venanzoni
Roberto Venanzoni
Paola AngeliniPaola Angelini
Paola Angelini
Mushroom polysaccharides, key components of fungal cell walls, exhibit various biological properties and hold significant medicinal and industrial value. These polysaccharides are known for their medicinal properties like antitumor, antioxidant, anticancer, immunomodulatory, and antiviral properties. Mushroom polysaccharides, particularly β-glucans, α-glucans, and chitin, have been associated with various health benefits. β-glucans are well studied for their bioactivities, while α-glucans and chitin have gained attention for their prebiotic, antimicrobial, and wound-healing properties. The therapeutic effects of these polysaccharides are closely linked to their chemical structures, including molecular weight, monosaccharide composition, and glycosidic bond types. This work aims to review the studies on mushroom polysaccharides, with a particular focus on their structural composition to deepen medicinal properties of mushroom polysaccharides. Also, the extraction methods and the pharmaceutical application of polysaccharides will be revised in this work.

1 March 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
Giancarlo Angeles FloresGiancarlo Angeles Flores
Giancarlo Angeles Flores
GCGaia Cusumano
Gaia Cusumano
RVRoberto Venanzoni
Roberto Venanzoni
Paola AngeliniPaola Angelini
Paola Angelini
Antimicrobial resistance (AMR) is a growing global health crisis that threatens the efficacy of antibiotics and modern medical interventions. The emergence of multidrug-resistant (MDR) pathogens, exacerbated by the misuse of antibiotics in healthcare and agriculture, underscores the urgent need for innovative solutions. (1) Background: AMR arises from complex interactions between human, animal, and environmental health, further aggravated by the overuse and inadequate regulation of antibiotics. Conventional treatments are increasingly ineffective, necessitating alternative strategies. Emerging approaches, including bacteriophage therapy, antimicrobial peptides (AMPs), nanotechnology, microbial extracellular vesicles (EVs), and CRISPR-based antimicrobials, provide novel mechanisms that complement traditional antibiotics in combating resistant pathogens. (2) Methods: This review critically analyzes advanced antibacterial strategies in conjunction with systemic reforms such as antimicrobial stewardship programs, the One Health framework, and advanced surveillance tools. These methods can enhance resistance detection, guide interventions, and promote sustainable practices. Additionally, economic, logistical, and regulatory challenges impeding their implementation are evaluated. (3) Results: Emerging technologies, such as CRISPR and nanotechnology, exhibit promising potential in targeting resistance mechanisms. However, disparities in resource distribution and regulatory barriers hinder widespread adoption. Public–private partnerships and sustainable agriculture practices are critical to overcoming these obstacles. (4) Conclusions: A holistic and integrated approach is essential for mitigating the impact of AMR. By aligning innovative therapeutic strategies with global health policies, fostering interdisciplinary collaboration, and ensuring equitable resource distribution, we can develop a sustainable response to this 21st-century challenge.

5 December 2024 in Plants
Verified
Journal Article
Open access
PDF file
Giancarlo Angeles FloresGiancarlo Angeles Flores
Giancarlo Angeles Flores
GCGaia Cusumano
Gaia Cusumano
Gökhan ZenginGökhan Zengin
Gökhan Zengin
MCMehmet Veysi Cetiz
Mehmet Veysi Cetiz
AUAbdullahi Ibrahim Uba
Abdullahi Ibrahim Uba
Paola AngeliniPaola Angelini
Paola Angelini
The present study investigates the chemical profile and biological activities of Polygonum istanbulicum M. Keskin, a species endemic to Turkey, aiming to explore its potential applications in pharmacology. We assessed its phenolic and flavonoid content by employing ethyl acetate, methanol, and water as extraction solvents. The methanol extract demonstrated the highest concentrations of these compounds, with liquid chromatography–quadrupole time-of-flight tandem mass spectrometry (LC-MS-qTOF) analysis identifying a wide range of bioactive substances, such as derivatives of quercetin and myricetin. Antioxidant capacity was evaluated using 2,2-Diphenyl-1-picrylhydrazyl (DPPH), 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS), cupric-reducing antioxidant capacity (CUPRAC), ferric-reducing antioxidant power (FRAP), and phosphomolybdenum assays, with the methanol extract showing the most potent activity (DPPH: 892.22 mg Trolox equivalent (TE)/g; ABTS: 916.21 mg TE/g; CUPRAC: 1082.69 mg TE/g; FRAP: 915.05 mg TE/g). Enzyme inhibition assays highlighted the efficacy of P. istanbulicum extracts against key enzymes, with potential implications for managing Alzheimer’s disease, hyperpigmentation, and type 2 diabetes. Cytotoxicity tests against various cancer cell lines showed notable activity, particularly with the aqueous extract on the HGC-27 cell line (IC50: 29.21 µg/mL), indicating potential for targeted anti-cancer therapy. Molecular docking and molecular dynamics simulations further supported the binding affinities of quercetin and myricetin derivatives to cancer-related proteins, suggesting significant therapeutic potential. This study underscores the value of P. istanbulicum as a source of bioactive compounds with applications in antioxidant, anti-cancer, and enzyme-inhibitory treatments.

29 December 2025 in Plants
Verified
Journal Article
Open access
PDF file
Giancarlo Angeles FloresGiancarlo Angeles Flores
Giancarlo Angeles Flores
GCGaia Cusumano
Gaia Cusumano
RVRoberto Venanzoni
Roberto Venanzoni
Paola AngeliniPaola Angelini
Paola Angelini
Natural products represent one of the most diverse and functionally sophisticated groups of bioactive molecules found across plants, fungi, bacteria, and marine organisms. Recent advances in genomics, metabolomics, and chemical ecology have fundamentally redefined how these compounds are generated, regulated, and functionally deployed in nature. Increasing evidence reveals that chemical diversity arises not solely from taxonomic lineage but from ecological pressures, evolutionary innovation, and multi-organism interactions that shape biosynthetic pathways over time. Hybrid metabolic architectures, context-dependent activation of biosynthetic gene clusters, and cross-kingdom metabolic integration collectively portray a biosynthetic landscape far more dynamic and interconnected than previously understood. At the same time, mechanistic studies demonstrate that natural products rarely act through single-target interactions. Instead, they influence redox dynamics, membrane architecture, chromatin accessibility, and intracellular signaling in distributed and synergistic ways that reflect both ecological function and evolutionary design. This review synthesizes emerging insights into the evolutionary drivers, ecological determinants, and mechanistic foundations of natural product diversity, highlighting the central role of silent biosynthetic gene clusters, meta-organismal chemistry, and network-level modes of action. By integrating these perspectives, we outline a conceptual and methodological framework capable of unlocking the vast biosynthetic potential that remains dormant within natural systems. Collectively, these advances reposition natural product research as a deeply integrative discipline at the intersection of molecular biology, ecology, evolution, and chemical innovation.